Across TCGA pan-cancer cohorts, RUFY2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RUFY2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RUFY2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RUFY2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where RUFY2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.619	0.922	<.001	37	view →
HNSC	DFS	Tertile	All	0.989	0.897	.026	16	view →
LUAD	DFS	Quartile	II,III,IV	0.184	0.621	.003	9	view →
PDAC	OS	Median	III,IV	1.000	0.537	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RUFY2 tumor-vs-normal RNA expression · all RUFY2 data types